Objectives Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all
non-small cell lung cancer (NSCLC) patients and patient subgroups. Results A total of 456 …

Background Identification of variable epidermal growth factor receptor (EGFR) gene
mutations in non-small cell lung cancer (NSCLC) is important for the selection of appropriate …

Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …

Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …

Background Convincing data on epidermal growth factor receptor (EGFR) mutations in
Chinese patients with non-small-cell lung cancer (NSCLC) remain limited. We investigated …

EGFR mutation frequencies in unselected Caucasian populations are unknown. This study
assesses the prevalence of EGFR mutations in an unselected population‐based cohort, and …

Epidermal growth factor receptor (EGFR) mutations are the strongest response predictors to
EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation …

Introduction: PIONEER (NCT01185314) was a prospective, multinational, epidemiological
study of epidermal growth factor receptor (EGFR) mutations in patients from Asia with newly …

Objectives Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-
mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial …

Background EGFR mutations cause inconsistent response to EGFR tyrosine-kinase
inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR …